A Multicenter Cross-sectional Study of Cardiac Ultrasound Phenotypes in Patients With Sepsis
1 other identifier
observational
200
1 country
1
Brief Summary
The heart, one of the most important organs for oxygen supply and consumption, is frequently involved in sepsis, i.e. septic cardiomyopathy, also known as septic myocardial suppression. The occurrence of septic myocardial suppression increases mortality in septic patients. Recent studies have found that left ventricular hyperdynamic state (EF \> 70%) is associated with intra-ICU mortality in septic patients, possibly because it reflects unresolved vascular paralysis from sepsis . For septic myocardial suppression, there is still a lack of uniform criteria for diagnosis, but it is well established that the cardiac ultrasound phenotype of septic myocardial suppression can be left ventricular systolic insufficiency (LVSD), left ventricular diastolic insufficiency (LVDD), right ventricular insufficiency (RVD), diffuse ventricular insufficiency, and mixed ventricular insufficiency. According to incomplete statistics, the prevalence of LVSD ranges from 12 to 60%, the prevalence of LVDD is higher, 20% to 79%, and the prevalence of RVD varies from 30% to 55%. However, based on the current understanding of septic myocardial suppression, the relationship between each staging and its prognosis is unclear, and echocardiography can rapidly identify septic myocardial suppression and guide the classification of septic myocardial suppression to further optimize the diagnosis and treatment process of sepsis, especially to avoid over-resuscitation during fluid resuscitation and perform reverse resuscitation in a timely manner to improve patient prognosis and reduce hospitalization time. The aim of this study is to classify and evaluate the prognosis of patients with different septic cardiac ultrasound phenotypes in multiple centers across China by measuring the right and left heart systolic and diastolic indices by echocardiography, recording the baseline conditions and clinical indices of patients, and combining them with the prognosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 23, 2021
CompletedStudy Start
First participant enrolled
November 23, 2021
CompletedFirst Posted
Study publicly available on registry
December 16, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 23, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 23, 2025
CompletedDecember 16, 2021
November 1, 2021
3 years
November 23, 2021
December 6, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
in-hospital mortality
Number of patient deaths divided by the total number
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
28-day mortality
Number of patient deaths within 28 days divided by the total number
From patient admission to day 28
Secondary Outcomes (2)
length of stay in the ICU
days from patient transfer to ICU to transfer out,an average of 1 week
number of days of mechanical ventilation
Days the patient was mechanically ventilated until the cessation of mechanical ventilation,an average of 1 week
Study Arms (6)
left ventricular systolic dysfunction(LVSD)
left ventricular diastolic dysfunction(LVDD)
right ventricular dysfunction(RVD)
diffuse ventricular dysfunction
hyperdynamic state left ventricular function
Normal
Eligibility Criteria
All patients with sepsis or septic shock who conform to Sepsis 3.0 diagnostic criteria and were more than or equal to 18 years of age who were admitted to each center were included. Sepsis was defined as an increase of ≥2 points from baseline in sequential organ failure assessment (SOFA) score due to infection; septic shock was defined as persistent hypotension on top of sepsis, requiring vasoactive drugs to maintain a mean arterial pressure(MAP) ≥65 mmHg and a blood lactate level \>2 mmol/L despite adequate fluid resuscitation.
You may qualify if:
- \- All patients with sepsis or septic shock who conform to Sepsis 3.0 diagnostic criteria
You may not qualify if:
- Patients with preexisting chronic heart disease such as cardiomyopathy, chronic pulmonary heart disease, severe cardiac valve disease, coronary heart disease, congenital heart disease, pericardial disease, etc. and with cardiac function ≥ grade III (NYHA classification) prior to sepsis.
- End-stage malignancies.
- Severe trauma.
- Pregnancy.
- Patients for whom transthoracic echocardiography data are not available.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fujian Provincial Hospital
Fuzhou, Fujian, 350000, China
Related Publications (1)
Zhang H, Wang X, Yin W, Zhang H, Liu L, Pan P, Zhu Y, Huang W, Xing Z, Yao B, Wang C, Lin T, Yu R, Shang X. A multicenter prospective cohort study of cardiac ultrasound phenotypes in patients with sepsis: Study protocol for a multicenter prospective cohort trial. Front Med (Lausanne). 2022 Jul 27;9:938536. doi: 10.3389/fmed.2022.938536. eCollection 2022.
PMID: 35966841DERIVED
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
November 23, 2021
First Posted
December 16, 2021
Study Start
November 23, 2021
Primary Completion
November 23, 2024
Study Completion
November 23, 2025
Last Updated
December 16, 2021
Record last verified: 2021-11